Erratum to: Successes and Failures for Drugs in Late-Stage Development for Alzheimer's Disease

Camryn Berk · Marwan N. Sabbagh

Published online: 11 December 2013
© Springer International Publishing Switzerland 2013

Erratum to: Drugs Aging (2013) 30:783–792
DOI 10.1007/s40266-013-0108-6

Page 790, column 1, section 4.8, lines 1–3: The sentence that previously read:

“Gantenerumab is another monoclonal antibody that has entered phase II/III clinical trials in the treatment of mild to moderate AD.”

Should read:

“Gantenerumab is another monoclonal antibody that has entered phase II/III clinical trials in the treatment of prodromal AD.”

The online version of the original article can be found under doi:[10.1007/s40266-013-0108-6](https://doi.org/10.1007/s40266-013-0108-6).

C. Berk · M. N. Sabbagh (✉)
The Cleo Roberts Center for Clinical Research,
Banner Sun Health Research Institute,
10515 West Santa Fe Drive, Sun City, AZ 85351, USA
e-mail: marwan.sabbagh@bannerhealth.com